FundingWatcher
Home / Startups / Top biotech startups / Biotech startups that raised Series A / Biotech startups that raised Series A in the United States

Biotech startups that raised Series A in the United States

Updated 16 Nov 2026

Reset
Biotech startups that raised Series A in the United States
One-time CSV
  • 1,063 funded companies, 908 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-biotech--series-a~united-states.csv1,063 rows × 18 columns
CompanyCityLast roundAmountDate
ZafrensSan DiegoSeries A$6.0M2026-11-03
Probably GeneticSan FranciscoSeries A$12.0M2026-10-15
BiotiaLong Island CitySeries A$9.0M2026-10-01
ai3BioPittsburghSeries A$48.0M2026-09-29
Arkea BioCharlestownSeries A$15.0M2026-09-29
RamonaDurhamSeries A$25.0M2026-09-22
ImpriMedPalo AltoSeries A$10.0M2026-09-18
Evia BioMinneapolisSeries A$5.5M2026-09-16

8 rows of the CSV in 5 of its 18 columns.

1,063
Startups
$40.0B
Total raised
128
Funded in the last 12 months
$5.4B
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

30 of 1,063
30 rows
Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
Zafrens Zafrens provides a throughput platform that links molecular profiles to cell phenotypes for drug discovery. Biotech San Diego Series A $6.0M 2026-11-03 $35.0M Liquid 2 Ventures, Global Brain Corporation, BlueYard Capital +2 11 to 50 2022
Probably Genetic Probably Genetic develops treatments aimed at improving the lives of patients with severe, complex diseases. Artificial intelligence San Francisco Series A $12.0M 2026-10-15 $22.9M Y Combinator, Khosla Ventures, TenOneTen Ventures +2 11 to 50 2018
Biotia Biotia is a health tech startup that offers AI solutions to diagnose and control infectious diseases. Artificial intelligence Long Island City Series A $9.0M 2026-10-01 $19.7M Everywhere Ventures, Sand Hill Angels, Tau Ventures +2 11 to 50 2016
ai3Bio ai3Bio develops cancer treatments for patients. Biotech Pittsburgh Series A $48.0M 2026-09-29 $103.0M UPMC Enterprises 11 to 50 2019
Arkea Bio Arkea Bio develops technology that reduces greenhouse gas emissions from agriculture. Biotech Charlestown Series A $15.0M 2026-09-29 $60.5M Breakthrough Energy Ventures, Overview, Rabo Ventures 11 to 50 2021
Ramona Ramona develops high-throughput microscopy tools for biology labs. Artificial intelligence Durham Series A $25.0M 2026-09-22 $59.7M National Science Foundation, National Institutes of Health, E14 Fund +1 11 to 50 2017
ImpriMed ImpriMed provides AI-driven precision medicine services to oncologists and pharmaceutical companies. Artificial intelligence Palo Alto Series A $10.0M 2026-09-18 $44.7M Plug and Play, Pear VC, Draper Associates +1 51 to 100 2017
Evia Bio Evia Bio develops non-DMSO cryopreservation solutions for life sciences. Biotech Minneapolis Series A $5.5M 2026-09-16 $5.7M Newchip Accelerator, Pleasant Bay Capital Partners, Walleye Tank 1 to 10 2019
Mithrl Mithrl is a software development company that builds custom NGS data workflows on demand. Artificial intelligence San Francisco Series A $20.0M 2026-09-15 $24.0M Bonfire Ventures 51 to 100 2023
TwoStep Therapeutics TwoStep Therapeutics develops tumor-targeting therapeutics for solid tumors. Biotech Palo Alto Series A $62.5M 2026-09-09 $90.1M NFX, 2048 Ventures, Alexandria Venture Investments +1 11 to 50 2023
Remedium Bio Remedium Bio develops gene therapy treatments for various diseases. Biotech Needham Series A $10.0M 2026-08-10 $13.8M National Science Foundation, MicroVentures, Longevitytech.fund +1 11 to 50 2020
Integrated Biosciences Integrated Bio develops multimodal biological datasets and AI for drug discovery against age-related diseases. Artificial intelligence Redwood City Series A $68.4M 2026-08-05 $85.6M Root Ventures, Reinforced Ventures, Mission BioCapital +2 11 to 50 2022
Dash Bio Dash Bio develops automated laboratory workflows and software to support drug development through bioanalysis services. Artificial intelligence Boston Series A $30.0M 2026-08-03 $47.5M Freestyle Capital, Swift Ventures, LifeX Ventures +1 11 to 50 2024
Transcripta Bio Transcripta Bio develops drugs at an accelerated pace with reduced risk. Biotech Palo Alto Series A $24.0M 2026-07-22 $34.4M BlueYard Capital, Jazz Venture Partners 11 to 50 2020
Xellar Biosystems Xellar Biosystems analyzes drug testing and treatment data using artificial intelligence. Artificial intelligence Newton Series A $29.5M 2026-06-30 $93.2M Legend Capital, Tiantu Capital, Zhengxuan Investment +1 11 to 50 2022
Waypoint Bio Waypoint Bio applies spatial biology to improve cell therapy development. Artificial intelligence New York Series A $20.0M 2026-05-27 $34.5M Village Global, Fifty Years, Hummingbird Ventures +2 11 to 50 2021
Kanvas Biosciences Kanvas Biosciences maps molecular interactions to support therapeutic discovery and human health. Biotech Monmouth Junction Series A $48.0M 2026-05-05 $76.4M DCVC, Pangaea Ventures, Germin8 Ventures +2 11 to 50 2020
Latus Bio Latus Bio develops gene therapies for central nervous system disorders using screened AAV capsids. Biotech Philadelphia Series A $43.0M 2026-05-04 $97.0M Gaingels, 8VC, Ben Franklin Technology Partners +1 11 to 50 2022
Gilgamesh Pharmaceuticals Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company developing psychedelic drugs to treat mental illness. Biotech New York Series A $60.0M 2026-03-24 $142.6M Y Combinator, Alumni Ventures, Gaingels +2 11 to 50 2019
Condor Software Condor Software is a financial intelligence platform that connects clinical, operational, and financial data in real time. Biotech San Diego Series A $24.0M 2026-03-18 $29.5M Plug and Play, MassChallenge, Pareto Holdings +1 11 to 50 2020
Stata DX Stata DX develops eRapid disease management technology for implementing custom biomarker panels in clinical studies. Biotech Cambridge Series A $400K 2026-02-27 $3.6M MassVentures 1 to 10 2022
Third Arc Bio Third Arc Bio develops multifunctional antibodies for inflammatory and immunology diseases. Biotech Boston Series A $52.0M 2026-02-04 $217.0M T. Rowe Price, Cormorant Asset Management, Foresite Capital +1 11 to 50 2022
Prenosis Prenosis develops data-driven diagnostic tools and precision medicine solutions for acute care conditions. Artificial intelligence Chicago Series A $20.0M 2026-01-29 $31.5M National Science Foundation, PACE Healthcare Capital, Defense Threat Reduction Agency (DTRA) 11 to 50 2014
Think Bioscience Think Bioscience designs and assembles medicines using living systems through synthetic biology. Biotech Boulder Series A $55.0M 2026-01-20 $78.3M National Science Foundation, Innovation Endeavors, Wireframe Ventures +2 11 to 50 2019
Prudentia Sciences Prudentia Sciences provides AI-powered asset diligence and valuation to reduce risk in drug development investment. Artificial intelligence Cambridge Series A $20.0M 2026-01-07 $27.0M Google Ventures, Iaso Ventures, Virtue 1 to 10 2023
Neurable Neurable develops AI tools for translating brain signals and brain-computer interface technology. Artificial intelligence Boston Series A $35.0M 2025-12-19 $57.3M National Science Foundation, Global Brain Corporation, Metaplanet +1 11 to 50 2015
Medra AI Medra AI builds an autonomous scientific experimentation platform that combines robotics with artificial intelligence. Artificial intelligence San Francisco Series A $52.0M 2025-12-11 $63.0M PharmStars 11 to 50 2021
Circular Genomics Circular Genomics develops RNA-based diagnostics for neurological diseases. Biotech Albuquerque Series A $15.0M 2025-12-01 $28.1M New Mexico Economic Development Department, Mountain Group Capital, Tramway Venture Partners +1 11 to 50 2021
Perelel Perelel makes supplements designed for different stages of a woman's reproductive life cycle. Biotech Los Angeles Series A $27.0M 2025-11-20 $41.7M Unilever Ventures, Willow Growth Partners, Selva Ventures 11 to 50 2018
AI Proteins AI Proteins designs and engineers miniprotein therapeutics using artificial intelligence. Artificial intelligence Boston Series A $42.5M 2025-11-19 $80.4M Intel Ignite, Lightchain Capital, Cobro Ventures 11 to 50 2021

Table 1. Biotech startups that raised Series A in the United States: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 1,063.

Largest rounds

Last 12 months
10 rows
# Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
1 Integrated Biosciences Integrated Bio develops multimodal biological datasets and AI for drug discovery against age-related diseases. Artificial intelligence Redwood City Series A $68.4M 2026-08-05 $85.6M Root Ventures, Reinforced Ventures, Mission BioCapital +2 11 to 50 2022
2 TwoStep Therapeutics TwoStep Therapeutics develops tumor-targeting therapeutics for solid tumors. Biotech Palo Alto Series A $62.5M 2026-09-09 $90.1M NFX, 2048 Ventures, Alexandria Venture Investments +1 11 to 50 2023
3 Gilgamesh Pharmaceuticals Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company developing psychedelic drugs to treat mental illness. Biotech New York Series A $60.0M 2026-03-24 $142.6M Y Combinator, Alumni Ventures, Gaingels +2 11 to 50 2019
4 Think Bioscience Think Bioscience designs and assembles medicines using living systems through synthetic biology. Biotech Boulder Series A $55.0M 2026-01-20 $78.3M National Science Foundation, Innovation Endeavors, Wireframe Ventures +2 11 to 50 2019
5 Third Arc Bio Third Arc Bio develops multifunctional antibodies for inflammatory and immunology diseases. Biotech Boston Series A $52.0M 2026-02-04 $217.0M T. Rowe Price, Cormorant Asset Management, Foresite Capital +1 11 to 50 2022
6 Medra AI Medra AI builds an autonomous scientific experimentation platform that combines robotics with artificial intelligence. Artificial intelligence San Francisco Series A $52.0M 2025-12-11 $63.0M PharmStars 11 to 50 2021
7 ai3Bio ai3Bio develops cancer treatments for patients. Biotech Pittsburgh Series A $48.0M 2026-09-29 $103.0M UPMC Enterprises 11 to 50 2019
8 Kanvas Biosciences Kanvas Biosciences maps molecular interactions to support therapeutic discovery and human health. Biotech Monmouth Junction Series A $48.0M 2026-05-05 $76.4M DCVC, Pangaea Ventures, Germin8 Ventures +2 11 to 50 2020
9 Latus Bio Latus Bio develops gene therapies for central nervous system disorders using screened AAV capsids. Biotech Philadelphia Series A $43.0M 2026-05-04 $97.0M Gaingels, 8VC, Ben Franklin Technology Partners +1 11 to 50 2022
10 AI Proteins AI Proteins designs and engineers miniprotein therapeutics using artificial intelligence. Artificial intelligence Boston Series A $42.5M 2025-11-19 $80.4M Intel Ignite, Lightchain Capital, Cobro Ventures 11 to 50 2021

Table 2. Biotech startups that raised Series A in the United States: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 National Science Foundation Entrepreneurship program Alexandria, United States 15 1% 5 Ramona, Remedium Bio, Prenosis
2 Y Combinator Startup accelerator Mountain View, United States 11 1% 3 Probably Genetic, Gilgamesh Pharmaceuticals, Arpeggio Bio
3 National Institutes of Health Entrepreneurship program Bethesda, United States 8 1% 1 Ramona
4 Alexandria Venture Investments Venture capital firm Pasadena, United States 8 1% 1 TwoStep Therapeutics
5 Alumni Ventures Angel group Manchester, United States 8 1% 1 Gilgamesh Pharmaceuticals
6 Andreessen Horowitz Venture capital firm Menlo Park, United States 8 1%
7 ARCH Venture Partners Venture capital firm Chicago, United States 8 1%
8 MassChallenge Startup accelerator Boston, United States 7 1% 1 Condor Software
9 Plug and Play Startup accelerator Sunnyvale, United States 6 1% 2 ImpriMed, Condor Software
10 F-Prime Venture capital firm Cambridge, United States 6 1%
11 Liquid 2 Ventures Venture capital firm San Francisco, United States 4 0% 1 Zafrens
12 Khosla Ventures Venture capital firm Menlo Park, United States 4 0% 2 Probably Genetic, Arpeggio Bio
13 Newchip Accelerator Startup accelerator Austin, United States 4 0% 1 Evia Bio
14 DCVC Venture capital firm Palo Alto, United States 4 0% 1 Kanvas Biosciences
15 Google Ventures Corporate venture arm San Francisco, United States 4 0% 1 Prudentia Sciences

Table 3. Biotech startups that raised Series A in the United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 899 85% $35.8B
Software 152 14% $4.7B
Artificial intelligence 94 9% $3.7B
Hardware 38 4% $617.8M
Cybersecurity 12 1% $106.3M
Energy 11 1% $445.4M
Commerce 6 1% $103.0M
Fintech 6 1% $50.0M
Education 4 0% $41.9M

Table 4. Biotech startups that raised Series A in the United States by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series A 1,063 100% $15.0M

Table 5. Biotech startups that raised Series A in the United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Cambridge 90 8%
San Francisco 77 7%
New York 66 6%
San Diego 62 6%
Boston 57 5%
Palo Alto 34 3%
Seattle 19 2%
South San Francisco 19 2%
Durham 15 1%
Houston 15 1%
Menlo Park 13 1%
Berkeley 12 1%

Table 6. Biotech startups that raised Series A in the United States by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
November 2026 2 2% $17.5M
October 2026 10 8% $501.3M
September 2026 16 12% $743.7M
August 2026 11 9% $298.2M
July 2026 6 5% $81.6M
June 2026 14 11% $423.2M
May 2026 11 9% $451.9M
April 2026 5 4% $315.5M
March 2026 11 9% $290.4M
February 2026 7 5% $285.1M
January 2026 15 12% $1.0B
December 2025 14 11% $624.2M
November 2025 6 5% $331.6M

Table 7. Biotech startups that raised Series A in the United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 108 10% $4.4B
2025 118 11% $5.0B
2024 73 7% $4.0B
2023 89 8% $3.0B
2022 107 10% $3.2B
2021 114 11% $6.0B

Table 8. Biotech startups that raised Series A in the United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 80 8%
2020 to 2022 210 20%
2015 to 2019 350 33%
2010 to 2014 208 20%
Before 2010 205 19%

Table 9. Biotech startups that raised Series A in the United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 353 34%
11 to 50 586 56%
51 to 100 65 6%
101 to 250 23 2%
251 to 500 5 0%
501 to 1,000 6 1%
1,001 to 5,000 2 0%
5,001 to 10,000 1 0%
10,001 or more 3 0%

Table 10. Biotech startups that raised Series A in the United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many biotech startups in the United States whose last round is Series A are on the list?
1,063, in the file dated 16 November 2026. 128 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 1,063 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Biotech startups that raised Series A in the United States: 1,063 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $349 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Biotech at other stages in United States

Other sectors that raised Series A in United States

Cite: FundingWatcher, 1,063 biotech companies in the United States whose most recent round is Series A, 16 November 2026. https://fundingwatcher.com/startups/biotech/series-a/united-states/